Phase III MIRANTIBUS trial: Results of 48 weeks treatment with divozilimab versus teriflunomide in relapsing multiple sclerosis

Authors
Category Primary study
ConferenceMSmilan2023
Year 2023
This article has no abstract
Epistemonikos ID: 74cac8a8699812d417ab5bab66305db1481e0b1e
First added on: Jan 10, 2026